1

Running head: SARS-COV-2 CT VALUE TRAJECTORY

1	SARS-CoV-2 virus dynamics in recently infected people – data from a household transmission
2	study
3	Alexandra M. Mellis, PhD <sup>1</sup> , Jennifer K Meece, PhD <sup>2</sup> , Natasha B. Halasa, MD, MPH <sup>3</sup> , James D.
4	Chappell, MD, PhD <sup>3</sup> , Huong Q. McLean, PhD, MPH <sup>2</sup> , Carlos G. Grijalva, MD, MPH <sup>3</sup> , Kayla E.
5	Hanson, MPH <sup>2</sup> , Yuwei Zhu, MD <sup>3</sup> , Ahra Kim, MSc <sup>3</sup> , Jessica Deyoe, MPH <sup>1</sup> , Lynn C. Ivacic, BS <sup>2</sup> ,
6	Carrie Reed, DSc, MPH <sup>1</sup> , H. Keipp Talbot, MD, MPH <sup>3</sup> , Melissa A. Rolfes, PhD, MPH <sup>1</sup>
7	Affiliations: <sup>1</sup> Centers for Disease Control and Prevention, Atlanta, Georgia, United States; <sup>2</sup>
8	Marshfield Clinic Research Institute, Marshfield, Wisconsin, United States; <sup>3</sup> Vanderbilt
9	University Medical Center, Nashville, Tennessee, United States

2

### SARS-COV-2 CT VALUE TRAJECTORY

1 Abstract 2 We used daily real-time reverse-transcription polymerase chain reaction (rRT-PCR) results from 3 67 cases of SARS-CoV-2 infection in a household transmission study to examine the trajectory 4 of cycle threshold (Ct) values, an inverse correlate of viral RNA concentration, from nasal 5 specimens collected between April 2020 and May 2021. Ct values varied over the course of 6 infection, across RT-PCR platforms, and by participant age. Specimens collected from children 7 and adolescents showed higher Ct values and adults aged  $\geq$ 50 years showed lower Ct values than 8 adults aged 18-49 years. Ct values were lower on days when participants reported experiencing 9 symptoms. 10 *Keywords*: SARS-CoV-2, cycle threshold values, age, viral dynamics, RT-PCR 11

### SARS-COV-2 CT VALUE TRAJECTORY

3

1	Note
2	Author Note: The findings and conclusions in this report are those of the authors and do
3	not necessarily represent the official position of the US Centers for Disease Control and
4	Prevention.
5	Funding statement: This study was supported by the Centers for Disease Control and
6	Prevention, (cooperative agreements IP001078 and IP001083). Dr. Grijalva was supported in
7	part by the National Institute for Allergy and Infectious Diseases (K24 AI148459). The work
8	used REDCap, which is supported by CTSA award No. UL1 TR002243 from the National
9	Center for Advancing Translational Sciences (NCATS) Clinical Translational Science Award
10	(CTSA) Program, Award Number 5UL1TR002243-03.
11	Conflict of interest statement: Dr. Grijalva reports grants from Campbell
12	Alliance/Syneos, the National Institutes of Health, the Food and Drug Administration, the
13	Agency for Health Care Research and Quality and Sanofi-Pasteur, and consultation fees from
14	Pfizer, Merck, and Sanofi-Pasteur. Dr. Halasa reports grant support from Sanofi-Pasteur and
15	Quidel.
16	Ethics statement: The study protocol was approved by Institutional Review Boards at
17	Vanderbilt University Medical Center and Marshfield Clinic Research Institute. CDC determined
18	this activity was conducted consistent with applicable federal law and CDC policy (see 45 C.F.R.
19	part 46; 21 C.F.R. part 56).
20	Correspondence: Alexandra M. Mellis, Influenza Division, Centers for Disease Control
21	and Prevention, 1600 Clifton Rd MS A-32, Atlanta, GA 30329, United States; T: (404) 498-4639;

22 fax (404) 639-3866; E: <u>qzv6@cdc.gov</u>.

4

#### SARS-COV-2 CT VALUE TRAJECTORY

1 Introduction 2 Cycle threshold (Ct) values are generated from real-time reverse-transcription 3 polymerase chain reaction (RT-PCR) assays and represent the minimum number of amplification 4 cycles needed to generate a signal for a specific target. Ct values are sometimes used as a 5 surrogate signal for SARS-CoV-2 viral loads[1], as they are inversely related to the amount of 6 virus present in the tested specimen, but are best interpreted as viral RNA template 7 concentration. Widespread availability has led to comparisons of Ct values at the patient[2] and 8 community[3] levels to infer associations with illness severity and patient characteristics. 9 However, Ct values can vary by assay, specimen type and quality, and time during the infection 10 course, especially complicating cross-sectional comparisons. Use of serial specimens collected 11 from one individual over the course of infection on the same assay can partially mitigate these 12 concerns, yet few investigations have used serial sampling to describe the natural history of 13 SARS-Co-V2 infection[4, 5] and even fewer have been conducted among the general 14 population[6, 7]. 15 We described SARS-CoV-2 RT-PCR Ct values in newly infected individuals who 16 underwent daily specimen collection as part of a multi-site prospective household transmission 17 study. We examined the impact of age and symptoms on Ct value trajectories to understand the 18 natural history of infection. 19 Methods 20 We conducted a household transmission study of SARS-CoV-2 in Tennessee and 21 Wisconsin[8] between April 2020 and May 2021. Index participants were first identified as non-22 hospitalized individuals who had tested positive for SARS-CoV-2 by a provider-ordered nucleic

23 acid amplification test, and resided with at least one other individual. Index participants and

## SARS-COV-2 CT VALUE TRAJECTORY

1	household contacts were enrolled and consented within 6 days of symptom onset in the index
2	participant. Study procedures included daily swabbing and symptom diaries (assessing presence
3	or absence of 16 symptoms, see Supplementary Table 1), for 14 consecutive days. All
4	participants also completed demographic surveys and self-reported pre-existing conditions
5	(asthma, chronic liver disease, premature birth, cardiac conditions, diabetes, cancer,
6	immunocompromising conditions, extreme obesity, kidney disease, or pregnancy) and, after
7	COVID-19 vaccines became available, vaccination status (which was also verified against health
8	records and immunization information systems).
9	Anterior nasal swabs were self-/parent-collected by study participants. Swabs were either
10	placed in viral transport media (Remel MicroTest M4RT ®, Lenexa, KS USA) and refrigerated
11	by participants for 7-10 days before transport, or placed in inactivating viral transport media
12	(Primestore®, Longhorn Vaccines & Diagnostics LLC, Bethesda, MD) and stored at room
13	temperature by participants for 1-3 days before transport to Marshfield Clinic Research Institute
14	or Vanderbilt University Medical Center laboratories for processing and freezing at -80°C prior
15	to testing. All specimens were tested by RT-PCR using either the CDC 2019-Novel Coronavirus
16	Real-Time RT-PCR Diagnostic Panel (EUA CDC-006-00019; with N1 and N2 gene targets and
17	RNase P control; CDC assay) or the ThermoFisher TaqPath <sup>TM</sup> COVID-19 ComboKit (with S and
18	N gene and ORF1ab targets and MS2 spike control; ThermoFisher assay). Only Ct values from
19	tests interpreted as positive (at least two SARS-CoV-2 target Ct values under 40) were analyzed.
20	As an additional quality control measure for this analysis, we excluded Ct values from any test
21	where the control (RNase P or MS2) result was interpreted as negative or where the RNase P
22	control target had a Ct value greater than 35 (though this exclusion did not change results).

#### SARS-COV-2 CT VALUE TRAJECTORY

6

Viral culture was conducted on positive specimens from a subset of participants tested
using the CDC assay. Wells were seeded with Vero E6-TMPRSS2 cells, to which 100µl of
participant specimen was added. Wells were monitored daily for culture positivity for five days
after inoculation. If >20% of cells were detached in wells exhibiting viral cytopathic effect, the
specimen was interpreted as culture positive. Additional detail of culture methods and results are
included in another report[9].

7 To examine trajectories of Ct values over the course of infection, we selected data from 8 household contacts who met the following criteria: individuals' first specimen must have been 9 negative, they must have tested positive in 3 or more tests, and all tests must have been 10 conducted on the same assay (Supplemental Figure 1). Days of lowest Ct values were defined 11 per target (N1, N2, N, S, or ORF1ab). We described Ct values over time using generalized 12 additive models controlling for the target of each assay (which also differed by assay type), with 13 a random effect spline for repeated measurements. We compared three models for age: 1) a null 14 model with no age effect and a single smoothing spline for the effect of each day since first 15 testing positive, representing a null hypothesis; 2) a model with categorical age (0-11, 12-17, 18-16 49, or  $\geq$ 50 years) and a single spline for time since first positive specimen, representing an 17 impact of age on Ct values but not necessarily on how those Ct values change over time; 3) a 18 model with both age and different splines for time since first positive in each age category, 19 representing an impact of age both on Ct values overall and on how trajectories change over 20 time. Model 2 had the lowest Akaike Information Criterion (AIC), and accounted for the greatest 21 deviance (50.4%). We also explored the effects of symptoms on each day of infection, 22 controlling for age as in Model 2; symptoms were considered as binary (whether the participant 23 reported any symptom on that day, yes/no) and categorical indicators (whether a participant was

## SARS-COV-2 CT VALUE TRAJECTORY

1	asymptomatic [never reported the symptom], pre-symptomatic, within symptomatic period, or
2	post-symptomatic that day); the binary model was chosen by smaller AIC and used for both the
3	primary results (on impact of any symptom) and post-hoc analysis of individual symptoms
4	(Supplemental Table 1). Similar models were used for analysis by other demographic factors.
5	Results
6	A total of 577 household contacts from 302 households were enrolled in the parent study
7	April 2020 - May 2021. Sixty-seven contacts from 50 households met our criteria for "incident
8	cases" (52.2% male; 82.1% non-Hispanic White; 19.4% with at least one underlying condition;
9	92.5% symptomatic; 26.8% aged 0-11, 16.4% aged 12-17, 40.3% aged 18-49, 16.4% aged ≥50;
10	10.4% having received only one dose of an mRNA COVID-19 vaccine before enrollment; Table
11	1 for demographics and Supplemental Figure 1 for inclusion/exclusion). Associations between
12	other demographics and Ct values are presented in Supplemental Table 3. Participants tested
13	positive for SARS-CoV-2 for a median of 10 days (interquartile range [IQR]: 8, 12 days,
14	although 58% of participants' last specimen collected were still positive for SARS-CoV-2 and
15	participants were tested for a median of 10 days following first positivity) and were symptomatic
16	for a median of 10 (IQR: 7, 13) days during follow-up. The median number of days from
17	symptom onset among incident cases to their first positive test was 0 (IQR: -1, 3) days, with
18	symptom onset preceding first positivity in 48% of symptomatic cases (see Supplemental Figure
19	2 for the proportion of participants who experienced symptoms prior to positivity for each
20	individual symptom). The median time from symptom onset to lowest Ct value was 4 (IQR: 2, 6)
21	days, indicating that symptom onset preceded lowest Ct value. The median time from first testing
22	positive to lowest Ct values among incident cases was 3 days (IQR: 2, 4 days). Among
23	symptomatic cases, the median time from symptom onset to lowest Ct value was 4 (IQR: 2, 6)

## SARS-COV-2 CT VALUE TRAJECTORY

1	days. Among the 93 specimens (from 13 participants, all culture positive at least once) that
2	underwent attempted culture, Ct values were lower in culture-positive specimens (median N1 Ct
3	value, 26.9 [IQR: 25.0, 30.0]; median N2 Ct value, 28.3 [IQR: 26.0, 30.7] from 63 specimens)
4	than in culture-negative specimens (median N1 Ct value, 35.6 [IQR: 34.1, 38.5]; median N2 Ct
5	value, 38.0 [IQR: 34.9, 39.0] from 30 specimens; Wilcox test p < .001).
6	A total of 544 specimens were analyzed, including 1384 Ct values against SARS-CoV-2
7	targets. Supplemental Table 2 reports Ct values by target and age, with sample sizes of
8	participants and tests. On average, children aged 0-11 years had Ct values that were 3.5 units
9	higher than adults aged 18-49 years (95% confidence interval [CI]: 2.8, 4.1; p < 0.001).
10	Adolescents aged 12-17 years also had higher average Ct values (absolute difference: 2.7; [CI:
11	1.9, 3.4]; $p < 0.001$ ) and older adults, aged $\geq 50$ years, had significantly lower Ct values (absolute
12	difference: -1.7; [CI: -2.4, -1.0]; p < 0.001) compared with adults aged 18-49 years (Figure 1). As
13	expected, Ct values differed between assays (higher in the CDC assay).
14	Reporting symptoms on a given day was associated with lower daily Ct values,
15	controlling for both target and age (absolute difference: -0.84 [CI: -1.0, -0.7], p < 0.001). Post-
16	hoc tests (Supplemental Table 1) showed that Ct values were significantly lower on days
17	participants reported having fatigue, fever, aches, chills, diarrhea, cough, chest tightness/pain,
18	shortness of breath, wheezing, nasal congestion, runny nose, sore throat, or headache. No
19	significant difference in Ct values were noted on days the participants experienced abdominal
20	pain, vomiting, or loss/change of taste/smell.
21	Discussion
22	Using data from incident cases from an intensive, prospective household study, this report
23	contributes data on Ct values early in the infection period, which are difficult to capture using

## SARS-COV-2 CT VALUE TRAJECTORY

1	other designs. Compared to adults aged 18-49 years, we observed that Ct values were higher
2	among children and adolescents (0-11 and 12-17 years; reflective of lower RNA levels), and
3	lower among older adults (≥50 years) in this largely pre-Alpha-predominant period. These results
4	are consistent with previous findings of variable Ct values by RT-PCR assay and time course of
5	infection [10]. Other studies have reported differences in Ct values across individuals who were
6	persistently asymptomatic[7, 11], and this analysis contributes that daily symptom status (and not
7	just overall symptom presentation) is associated with daily Ct values, with lower Ct values on
8	days when participants experienced symptoms. Furthermore, dates of symptom onset preceded
9	dates of lowest Ct values by a median of 4 days, suggesting relatively longer periods of rising
10	viral RNA concentration following symptom onset compared to other studies[4, 7].
11	While other studies have reported significant differences in Ct values as a function of age,
12	the direction and interpretation of these results has differed. Cross-sectional and retrospective
13	studies examining Ct values among children have observed lower Ct values in children under the
14	age of 5 compared to adults over age 18[12] and compared to older children between age 5 and
15	14[13]. In this analysis of specimens collected daily since the first positive test result, Ct values
16	among children and adolescents were higher than values among adults aged 18-49 years. The
17	discrepancies between these findings and prior reports merit further investigation, and may have
18	been driven by differences in the severity of illness, the time during infection, circulating
19	variants, or the prospective versus cross-sectional study design.
20	Describing dynamics of Ct values based on frequent, systematic sampling of individuals
21	over time ameliorates multiple concerns with the use of this data; however, these findings must
22	still be interpreted with caution. Our selection of incident cases may have biased the sample
23	towards those exhibiting delayed replication. Sample size and study period are also limitations,

## SARS-COV-2 CT VALUE TRAJECTORY

1	especially in our ability to assess the impact of vaccination status or dissociate vaccination or
2	other demographics from age. Ct values also cannot be converted to a quantitative representation
3	of viral load, and cannot be used to directly infer differences in infectiousness. However, despite
4	these limitations, clinical interpretation of Ct values (or their trajectories) may be "tempting"
5	(IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for
6	clinical decision-making, page 3) [14]. The present data are directly relevant to these
7	interpretations. Specifically, specimens that were collected within 4 days of symptom onset may
8	represent periods when Ct values are still declining.
9	These findings contribute to our understanding of RT-PCR Ct values during SARS-CoV-
10	2 infections over a broad range of ages, in a community setting with mostly mildly symptomatic
11	illness, and among individuals with a known date of first shedding. While these data were
12	collected prior to Delta and Omicron circulation, and prior to widespread vaccination, they may
13	provide context for interpreting trajectories in Ct values in similar populations during later
14	SARS-CoV-2 outbreaks.

#### SARS-COV-2 CT VALUE TRAJECTORY

#### 11

#### References

- 2 1. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value.
- 3 Clinical Infectious Diseases **2020**; 71:2252-4.

- 4 2. Magleby R, Westblade LF, Trzebucki A, et al. Impact of Severe Acute Respiratory Syndrome
- 5 Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With
- 6 Coronavirus Disease 2019. Clinical Infectious Diseases 2020.
- 7 3. Tso CF, Garikipati A, Green-Saxena A, Mao Q, Das R. Correlation of Population SARS-CoV-
- 8 2 Cycle Threshold Values to Local Disease Dynamics: Exploratory Observational Study. JMIR
- 9 public health and surveillance **2021**; 7:e28265.
- 10 4. Kissler SM, Fauver JR, Mack C, et al. Viral dynamics of acute SARS-CoV-2 infection and
- 11 applications to diagnostic and public health strategies. PLoS Biol 2021; 19:e3001333-e.
- 12 5. Ke R, Martinez PP, Smith RL, et al. Longitudinal analysis of SARS-CoV-2 vaccine
- 13 breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution.
- 14 medRxiv **2021**:2021.08.30.21262701.
- 15 6. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics
- 16 of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the
- 17 UK: a prospective, longitudinal, cohort study. Lancet Infect Dis 2021.
- 18 7. Stankiewicz Karita HC, Dong TQ, Johnston C, et al. Trajectory of Viral RNA Load Among
- 19 Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With
- 20 COVID-19 Symptom Onset and Severity. JAMA Network Open 2022; 5:e2142796-e.
- 21 8. Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 infections in
- 22 households—Tennessee and Wisconsin, April–September 2020. Morbidity and Mortality Weekly
- 23 Report **2020**; 69:1631.

#### SARS-COV-2 CT VALUE TRAJECTORY

- 1 9. Bonenfant G, Deyoe J, Wong T, et al. Surveillance and correlation of SARS-CoV-2 viral RNA,
- 2 antigen, virus isolation, and self-reported symptoms in a longitudinal study with daily sampling.
- 3 medRxiv **2021**:2021.12.23.21268319.
- 4 10. Rhoads D, Peaper DR, She RC, et al. College of American Pathologists (CAP) Microbiology
- 5 Committee Perspective: Caution Must Be Used in Interpreting the Cycle Threshold (Ct) Value.
- 6 Clinical Infectious Diseases **2020**; 72:e685-e6.
- 7 11. Salvatore PP, Dawson P, Wadhwa A, et al. Epidemiological Correlates of Polymerase Chain
- 8 Reaction Cycle Threshold Values in the Detection of Severe Acute Respiratory Syndrome
- 9 Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2021; 72:e761-e7.
- 10 12. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-Related
- 11 Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
- 12 2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). JAMA
- 13 Pediatrics **2020**; 174:902-3.
- 14 13. Strutner J, Ramchandar N, Dubey S, et al. Comparison of Reverse-Transcription Polymerase
- 15 Chain Reaction Cycle Threshold Values From Respiratory Specimens in Symptomatic and
- 16 Asymptomatic Children With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
- 17 Clinical Infectious Diseases **2021**; 73:1790-4.
- 18 14. Infectious Diseases Society of America AfMP. IDSA and AMP joint statement on the use of
- 19 SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making, 2021:3.
- 20 15. McLean HQ, Grijalva CG, Hanson KE, et al. Household Transmission and Clinical Features
- 21 of SARS-CoV-2 Infections by Age in 2 US Communities. medRxiv : the preprint server for
- 22 health sciences **2021**:2021.08.16.21262121.

# Inserts

Table 1. Characteristics of 67 incident cases of S.	ARS-CoV-2 infection
---	---------------------

	Overall	Age 0-11	Age 12-17	Age 18-49	Age 50+	p value
n	67	18	11	27	11	
Partially vaccinated <sup>†</sup> (n, %)	7 (10.4)	0 (0.0)	1 (9.1)	4 (14.8)	2 (18.2)	0.337
Male (n, %)	35 (52.2)	9 (50.0)	5 (45.5)	16 (59.3)	5 (45.5)	0.807
Race-ethnicity (n, %)						0.754
Hispanic	10 (14.9)	3 (16.7)	2 (18.2)	3 (11.1)	2 (18.2)	
Non-white, non-Hispanic	2 (3.0)	0 (0.0)	0 (0.0)	2 (7.4)	0 (0.0)	
Non-Hispanic White	55 (82.1)	15 (83.3)	9 (81.8)	22 (81.5)	9 (81.8)	
Any underlying condition (n, %)	13 (19.4)	2 (11.1)	1 (9.1)	6 (22.2)	4 (36.4)	0.296
Number of household members, median [IQR]	6.0 [4.0, 6.0]	6.0 [6.0, 6.0]	6.0 [5.0, 7.0]	4.0 [3.8, 4.0]	2.0 [2.0, 3.0]	0.04
Days from first positive specimen to lowest Ct value, median [IQR]	3.0 [2.0, 4.0]	2.0 [1.0, 3.0]	3.0 [2.0, 3.0]	4.0 [3.0, 5.0]	3.0 [2.0, 3.3]	<0.00 1
Still positive at end of follow-up, n (%)	39 (58.2)	7 (38.9)	5 (45.5)	19 (70.4)	8 (72.3)	0.11
Duration of positivity in days*, median [IQR]	10.0 [8.0, 12.0]	8.0 [7.3, 9.8]	10.0 [5.5, 11.0]	10.0 [9.0, 12.0]	10.0 [8.0, 13.0]	-
Symptomatic (n, %)	62 (92.5)	16 (88.9)	10 (90.9)	26 (96.3)	10 (90.9)	0.805
Symptom duration in days*‡, median [IQR]	10.0 [7.0, 13.0]	6.5 [4.5, 10.3]	9.0 [4.0, 13.0]	12.0 [9.3, 13.8]	11.5 [10.3, 13.0]	-
Days from symptom onset to first positive specimen <sup>‡</sup> , median [IQR]	0.0 [-1.0, 3.0]	0.0 [-2.0, 2.0]	0.0 [-1.0, 3.0]	1.0 [-1.0, 3.0]	0.0 [0.0, 4.0]	0.315
Days from symptom onset to lowest Ct <sup>+</sup> , median [IQR]	4.0 [2.0, 6.0]	3.0 [0.0, 4.0]	3.0 [0.3, 6.0]	4.0 [3.0, 6.0]	3.5 [3.0, 7.0]	0.008

\*Comparison not performed due to censored data.

## SARS-COV-2 CT VALUE TRAJECTORY

<sup>†</sup>Vaccination status defined at the time of study enrollment. Partial vaccination indicates having received one dose of a two-dose mRNA COVID-19 vaccine series. All other study participants had no vaccination documented.

§CDC assay indicates the CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel. Remaining participants were tested with the ThermoFisher TaqPathTM COVID-19 ComboKit.

<sup>‡</sup>The number of days of symptoms, days from symptom onset to first positive test, and symptom onset to peak Ct are calculated only among symptomatic incident cases. The time from symptom onset to first positive specimen and from symptom onset to lowest Ct value are calculated per target for the CDC assay N1 and N2 targets, and ThermoFisher assay N, S, and ORF1ab targets before taking the median of all time differences.

### SARS-COV-2 CT VALUE TRAJECTORY

Figure 1. Ct value curves over time since each participant first tested positive against each target, within age groups



Figure 1. Ct value curves over time since each participant first tested positive against each target, within age groups. Dots represent mean observed values within age groups, and vertical bars show bootstrapped 95% confidence intervals. Smooth lines represent predicted values from the Generalized Additive Model of Ct values over time, accounting for age and repeated measurements. Panel A shows results from participants age 0-11 (triangle) compared to the reference group, age 18-49 (circle); Panels B and C repeat this comparison with age 12-17 or 50+. Each plot from left to right represents a SARS-CoV-2 target from one of the two included testing platforms (CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel or the ThermoFisher TaqPathTM COVID-19 ComboKit).